The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis

Table 1

The details of each included study.

Study	Country	Study design	Treatment		Sample size		Dosage	Follow-up period	Date of study	Eligibility criteria
			Experimental	Control	Experimental	Control
Mehmet S (2019)	Turkey	Retrospective study	Mirabegron	Control	34	34	50 mg/day	15 days	Apr 2017 to Jan 2018	Patients with stones smaller than 10 mm that were located in the intramural ureteral segment
Göksel B (2019)	Turkey	RCT	Mirabegron	Control	62	63	50 mg/day	4 weeks	Jun 2017 to Aug 2018	Patients aged 18–75 years were scheduled to undergo ureteroscopy for ureteral stones
Göksel B (2020)	Turkey	RCT	Mirabegron	Control	56	59	50 mg/day	4 weeks	NA	Patients had ureter stones in size between 4 and 10 mm
Qing T (2021)	China	RCT	Mirabegron	Control	45	45	50 mg/day	4 weeks	Dec 2019 to Nov 2020	Patients aged 18–65 years were diagnosed as distal ureteral stones ≤10 mm

RCT, randomized controlled trial; NA, not available.